Decision Diagnostics Corp.
Decision Diagnostics Corp. (DECN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
decn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Pharmaceuticals · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Decision Diagnostics Corp.You DECN | $0M | N/A | — | — |
 Amarantus BioScience Holdings, Inc. AMBS | $0M | N/A | — | -$0.01 |
 AXM Pharma, Inc. AXMP | $0M | N/A | — | — |
 iBX Group, Inc. IBXG | $0M | N/A | — | — |
 Itoco Inc. ITMC | $0M | N/A | — | -$0.01 |
 Ligand Pharmaceuticals Incorporated LGND | $4.8B | 29.38x | — | $6.44 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Decision Diagnostics Corp. (DECN) measures how much investors pay for each dollar of the company's trailing earnings. DECN's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
DECN pe ratio · 6 questionsDECN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via DECN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Decision Diagnostics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09